A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Pharmaceutical giant Gilead Sciences has agreed to donate drugs that reduce the risk of HIV transmission for up to 200,000 people a year, the Trump administration says.
The agreement between Gilead and the Trump administration will last until at least Dec. 31, 2025, and possibly through the end of 2030, Health and Human Services Secretary Alex Azar said in a statement Thursday. Gilead will donate its PrEP medication Truvada, which is used to reduce the risk of HIV infection and usually sells for $1,600 to $2,000 a month in the United States.
The deal will "help us achieve our goal of ending the HIV epidemic in America!," President Donald Trump said in a tweet.
Trump has pledged to end the HIV epidemic in the United States by 2030, a goal long sought by public health advocates. According to the latest data from the Joint United Nations Programme on HIV/AIDS, about 36.9 million people worldwide are living with HIV or AIDS, and an estimated 21.7 million of those people are using antiretroviral medicines to suppress the infection.
Gilead said it will donate its Truvada pill until a second-generation version, Descovy, becomes available. The Trump administration has agreed to cover costs associated with distributing the drugs.
"Securing this commitment is a major step in the Trump Administration's efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030," Azar said.
California-based Gilead Sciences dominates the $26 billion-a-year HIV medication market.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.